cease and desist tirzepatide Novo sues Lilly, claiming misleading ads in weight-loss drug battle The fun never ends. Let’s

When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)

GHK-Cu is a research compound intended for research use only not for human consumption

By empowering our community with reliable information and effective products, we aim to help you take control of your health

Through systematic variation of receptor potency ratios, the authors identified compounds achieving maximal weight loss and glucose control in obese mice, confirming that receptor balance cannot yet be predicted in silico due to complex receptor crosstalk and feedback regulation

In Latin America, where obesity rates have grown faster than in other parts of the world, the drug remains unaffordable for the bulk of the population